• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Inmune Bio Inc (NQ: INMB )

    8.070 -0.350 (-4.16%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 2, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 153,124
    Open 8.330
    Bid (Size) 8.000 (1)
    Ask (Size) 8.660 (4)
    Prev. Close 8.420
    Today's Range 7.990 - 8.500
    52wk Range 6.500 - 14.74
    Shares Outstanding 17,703,692
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    INmune Bio, Inc. Completes Blinded Interim Analysis of Phase II Alzheimer’s Disease Trial
    From INmune Bio, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Thursday's Pre-Market Session
    Via Benzinga

    Performance

    YTD
    -28.07%
    -28.07%
    1 Month
    -16.20%
    -16.20%
    3 Month
    -26.30%
    -26.30%
    6 Month
    -28.07%
    -28.07%
    1 Year
    -13.04%
    -13.04%

    More News

    Read More
    INmune Bio Inc. to Join Russell 3000® Index
    From INmune Bio, Inc.
    Via GlobeNewswire
    INmune Bio: Q4 Earnings Insights
    Via Benzinga
    A Preview Of INmune Bio's Earnings
    Via Benzinga
    INMB Stock Earnings: INmune Bio Misses EPS, Misses Revenue for Q1 2024
    Via InvestorPlace
    INmune Bio Inc. to Report First Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, May 9
    From INmune Bio, Inc.
    Via GlobeNewswire
    INmune Bio Inc. Provides Update on Two Patients from the Phase 1b Alzheimer’s Disease Trial who Continue to Receive XPro™ Under Compassionate Use for Over Three Years
    From INmune Bio, Inc.
    Via GlobeNewswire
    INmune Bio Inc. Completes First Cohort and Initiates Second Cohort of Phase 1/2 Study of INKmune™ Natural Killer Cell Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer
    From INmune Bio, Inc.
    Via GlobeNewswire
    INmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
    From INmune Bio, Inc.
    Via GlobeNewswire
    INmune Bio Inc. Announces 24-Month Stability Validation of XPro™ for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity Assay
    From INmune Bio, Inc.
    Via GlobeNewswire
    INmune Bio Inc. Raises Approximately $4.8 Million in Gross Proceeds Through Registered Direct Offering with Officers, Employees and Directors Purchasing Approximately 20% of the Offering
    From INmune Bio, Inc.
    Via GlobeNewswire
    INmune Bio Inc. Presents Data on INB03’s Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024
    From INmune Bio, Inc.
    Via GlobeNewswire
    INMB Stock Earnings: INmune Bio Misses EPS, Misses Revenue for Q4 2023
    Via InvestorPlace
    Earnings Scheduled For March 28, 2024
    Via Benzinga
    INmune Bio Inc. to Report Fourth Quarter 2023 Financial Results and Provide a Corporate Update on Thursday, March 28
    From INmune Bio, Inc.
    Via GlobeNewswire
    INmune Bio CSO and Co-Founder Mark Lowdell, Ph.D. Receives The ISCT Career Achievement Award in Cell and Gene Therapy
    From INmune Bio, Inc.
    Via GlobeNewswire
    INmune Bio Reports Significant EEG Improvement in Alzheimer’s Patients Treated with XPro™
    From INmune Bio, Inc.
    Via GlobeNewswire
    INmune Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
    From INmune Bio, Inc.
    Via GlobeNewswire
    INmune Bio to Participate in Baird’s Biotech Discovery Series Webcast on February 13, 2024
    From INmune Bio, Inc.
    Via GlobeNewswire
    INmune Bio Announces FDA Removal of Clinical Hold for Alzheimer’s Disease Program
    From INmune Bio, Inc.
    Via GlobeNewswire
    Why Is Elevai Labs (ELAB) Stock Up Today?
    Via InvestorPlace
    Why Elevai Labs Stock Is Trading Higher
    Via Benzinga
    ELEVAI Labs, Inc. Acquires Worldwide License Agreement for Proprietary Stem Cell Manufacturing Technology
    From Elevai Labs Inc.
    Via GlobeNewswire
    INmune Bio Announces First Patient Dosed in a Phase 1/2 Study of INKmune™ in Patients with Metastatic Castration-Resistant Prostate Cancer
    From INmune Bio, Inc.
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.